adavosertib (AZD1775) / Merck (MSD), AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

35 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
adavosertib (AZD1775) / AstraZeneca
ADAGIO, NCT04590248 / 2020-000138-16: A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Completed
2b
109
Europe, Canada, US
Adavosertib, AZD1775
AstraZeneca, Parexel
Uterine Serous Carcinoma
05/22
02/23
ACTRN12619001185156: Targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC)

Recruiting
2
96
 
Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Ovarian Cancer, Cancer of the falllopian tube, Primary peritoneal cancer
 
 
NCT02087176: A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Terminated
2
48
US
AZD1775, MK-1775; Neulasta, AZD1775 Placebo, Antimitotic Agent, antiimitotic agent, pegfiligrastim, Neulasta
AstraZeneca
Previously Treated Non Small Cell Lung Cancer
05/15
05/15
NCT02087241: Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Terminated
2
22
US
AZD1775, MK-1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
AstraZeneca
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
06/15
06/15
NCT01935037: A Study of Cisplatin With or Without MK-1775 in Squamous Cell Cancer of the Head and Neck

Not yet recruiting
2
76
Canada
MK-1775, MK-1775 placebo, Cisplatin, Platinol
University Health Network, Toronto
Squamous Cell Cancer of the Head and Neck, Recurrent, Metastatic
09/15
03/16
2010-019106-16: Phase II and Pharmacological Study with Wee-1 Inhibitor MK-1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer that Show Early Relapse (< 3 months) or Progression during Standard First Line Treatment with Carboplatin – Paclitaxel Combination Therapy.

Ongoing
2
32
Europe
MK-1775, MK-1775,
Netherlands Cancer Institute (NKI)+31
p53 mutated epithelial ovarian cancer (after first line standard therapy)
 
 
NCT02196168: Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Terminated
2
6
Canada
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, placebo therapy, PLCB, sham therapy, WEE1 Inhibitor AZD1775, AZD-1775, AZD1775, MK-1775, MK1775
National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
04/16
04/16
NCT01357161 / 2011-002803-13: A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Completed
2
136
NA
adavosertib, MK-1775, Placebo, paclitaxel, Taxol, carboplatin, paraplatin
Merck Sharp & Dohme LLC
Ovarian Cancer
08/16
08/16
NCT02688907: Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Terminated
2
7
RoW
AZD1775
Samsung Medical Center
Small Cell Lung Cancer
12/17
09/18
NCT02666950: WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
2
3
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775, AZD-1775, AZD1775, MK-1775, MK1775
Mayo Clinic, National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
09/18
10/18
NCT02593019: Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Completed
2
24
RoW
AZD1775
Samsung Medical Center
Small Cell Lung Cancer
10/18
10/18
NCT02272790 / 2015-000886-30: Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
2
95
Europe, Canada, US
Adavosertib, MK1775, Paclitaxel, Taxol, Carboplatin, Paraplatin, Gemcitabine, PLD
AstraZeneca
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
12/18
03/23
NCT03012477: CISPLATIN + AZD-1775 In Breast Cancer

Completed
2
34
US
Cisplatin, Platinol, AZD1775
Dana-Farber Cancer Institute, AstraZeneca
Triple-negative Metastatic Breast Cancer
05/19
11/20
NCT03718143: AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Terminated
2
6
US
Combination AZD1775 with AraC, AZD1775 only
NYU Langone Health
Myelofibroses, Acute Myeloid Leukemia, Myelodysplastic Syndromes
09/19
09/19
OLAPCO, NCT02576444: OLAParib COmbinations

Terminated
2
67
US
AZD2281, Olaparib, AZD5363, AZD1775, AZD6738
Joseph Paul Eder, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, The Cleveland Clinic
Cancer
11/19
11/19
NCT02448329: Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Completed
2
26
RoW
AZD1775, paclitaxel
Samsung Medical Center
Advanced Gastric Adenocarcinoma
12/19
04/21
BALTIC, NCT02937818 / 2016-001202-42: A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Checkmark Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Mar 2022 - Mar 2022: Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Completed
2
72
Europe, RoW
Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
AstraZeneca
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
06/20
11/23
VIOLETTE, NCT03330847 / 2017-002361-22: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Active, not recruiting
2
273
Europe, Canada, US, RoW
Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
AstraZeneca
Metastatic Triple Negative Breast Cancer
11/20
09/24
NCT02194829: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Completed
2
8
US
AZD1775, Adavosertib, MK-1775, Gemcitabine, 2'-Deoxy-2', 2'-difluorocytidine monohydrochloride, Gemzar, Nab-paclitaxel, ABI-007, paclitaxel protein-bound particles for injectable suspension
National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma
06/21
12/22
NCT01827384: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Completed
2
208
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
06/21
10/21
NCI-2014-00620, NCT02101775: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
124
Canada, US, RoW
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
02/22
02/25
NCT03253679: AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Completed
2
31
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
10/22
10/22
M10MKO, NCT01164995: Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

Completed
2
24
Europe
MK-1775 and carboplatin, CBDCA
The Netherlands Cancer Institute, Merck Sharp & Dohme LLC
Epithelial Ovarian Cancer
04/23
04/23
NCT05212025: Adavosertib and Gemcitabine in Advanced Pancreatic

Withdrawn
2
0
NA
Adavosertib, AZD 1775, Gemcitabine, Gemzar
James Cleary, MD, PhD, AstraZeneca, Lustgarten Foundation, Stand Up To Cancer
Pancreatic Cancer
06/23
12/23
NCT02513563: AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Completed
2
42
US
Carboplatin, Paraplatin®, Paclitaxel, TAXOL®, AZD1775, MK1775
H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
11/22
11/23
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting
2
200
Canada
Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin
Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation
Prostate Cancer
12/24
12/25
NCT03668340: AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Active, not recruiting
2
49
US
AZD1775
Dana-Farber Cancer Institute, AstraZeneca
Uterine Cancer
12/24
12/25
NCT04439227: Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Active, not recruiting
2
35
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
06/25
06/25
NCT03284385: Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Active, not recruiting
2
60
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
08/24
08/24
EFFORT, NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting
2
104
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Ceralasertib, AZD6738
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
12/24
12/24
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Nov 2019 - Nov 2019: Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography, EC, Erdafitinib, Balversa, JNJ-42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC-0068, RG-7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Osimertinib, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
12/25
12/25
NCT01076400 / 2009-017054-12: A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

Terminated
1/2
7
NA
adavosertib, MK-1775, Topotecan, Cisplatin, Placebo to adavosertib
Merck Sharp & Dohme LLC
Cervical Cancer
06/11
06/11
NCT02037230: Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Completed
1/2
34
US
MK-1775, Gemcitabine, Radiation Therapy
University of Michigan Rogel Cancer Center
Adenocarcinoma of the Pancreas
08/18
08/18
NCT02095132: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Completed
1/2
76
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E
National Cancer Institute (NCI)
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
12/20
06/23
ESMART, NCT02813135 / 2016-000133-40: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting
1/2
460
Europe
Ribociclib, Kisqali, LEE011, Topotecan, Hycamtin, Temozolomide, Temodar, Everolimus, Afinitor, Adavosertib, AZD1775, Carboplatin, Paraplatin, Olaparib, Lynparza, Irinotecan, Camptosar, CPT-11, Vistusertib, AZD2014, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Selumetinib, Koselugo, Enasidenib, Idhifa, Lirilumab, BMS-986015, Fadraciclib, CYC065, Cytarabine, Arabinosylcytosine, Cytosar-U, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Ceralasertib, AZD6738, Futibatinib, Tas-120, Capmatinib, Tabrecta, INC280
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pediatric Cancer
08/27
08/27

Download Options